No description available.

O excesso de iodo inibe a proliferação celular e secreção hormonal, enquanto retarda os efeitos oncogênicos da ativação de RET/PTC3 na célula folicular tiroidiana. A mutação BRAF (T1799A) é a mais prevalente no câncer de tiroide, e modelo transgênico desenvolve câncer que progride para histotipo agressivo. Altos níveis de microRNAs (miRNAs) do cluster miR-17-92 estão associados a histotipos agressivos de câncer de tiroide e modulam a tradução de mRNAs alvo componentes de vias de sinalização oncogênicas. Neste estudo, avaliamos a influência da alta dose de iodo sobre miRNAs frente ativação do oncogene BRAF e seu efeito na biologia da célula folicular tiroidiana. A indução de BRAFT1799A ativa uma robusta expressão de miR-17-92 enquanto alta dose de iodo bloqueia este efeito na célula tiroidiana. miR-19 inibe a tradução de Smad4 e bloqueia a transdução do sinal de TGFb, efeito revertido pelo iodo. O iodo interfere na expressão de miR-17-92 por bloquear ativação da sinalização Notch induzida por BRAF. Estes resultados indicam que o iodo protege a célula folicular tiroidiana durante a indução de BRAFT1799A, revertendo a ativação dos miRNAs oncogênicos do cluster miR-17-92 e restaurando os níveis protéicos de Smad4 por interferir na via de sinalização Notch. / Iodine excess blocks cell proliferation and inhibits hormone synthesis, while delays oncogenic effects of RET/PTC3 activation in thyroid follicular cells. BRAF mutation (T1799A) is the most prevalent genetic alteration in thyroid cancer, and transgenic mice model for BRAF develops thyroid cancer that progress to aggressive histotypes. High levels of microRNAs (miRNAs) of miR-17-92 cluster are associated to aggressive thyroid cancer and modulate translation of target mRNAs in oncogenic signaling pathways. In this study, we evaluated the influence of high dose iodine in miRNAs under BRAF oncogene activation, and its effects in thyroid follicular cell biology. BRAF induction induces high expression of miR-17-92 while high dose iodine blocks this effect in thyroid follicular cells. miR-19 inhibits Smad4 translation and impairs TGFb signaling transduction, effect reverted by iodine. Iodine modulates miR-17-92 expression by interfering in BRAF-induced Notch signaling activation. These results indicate that iodine protects thyroid follicular cell during BRAF induction, reverting oncogenic miR-17-92 activation and restoring protein levels of Smad4 by Notch signaling modulation.

O excesso de iodo inibe a proliferação celular e secreção hormonal, enquanto retarda os efeitos oncogênicos da ativação de RET/PTC3 na célula folicular tiroidiana. A mutação BRAF (T1799A) é a mais prevalente no câncer de tiroide, e modelo transgênico desenvolve câncer que progride para histotipo agressivo. Altos níveis de microRNAs (miRNAs) do cluster miR-17-92 estão associados a histotipos agressivos de câncer de tiroide e modulam a tradução de mRNAs alvo componentes de vias de sinalização oncogênicas. Neste estudo, avaliamos a influência da alta dose de iodo sobre miRNAs frente ativação do oncogene BRAF e seu efeito na biologia da célula folicular tiroidiana. A indução de BRAFT1799A ativa uma robusta expressão de miR-17-92 enquanto alta dose de iodo bloqueia este efeito na célula tiroidiana. miR-19 inibe a tradução de Smad4 e bloqueia a transdução do sinal de TGFb, efeito revertido pelo iodo. O iodo interfere na expressão de miR-17-92 por bloquear ativação da sinalização Notch induzida por BRAF. Estes resultados indicam que o iodo protege a célula folicular tiroidiana durante a indução de BRAFT1799A, revertendo a ativação dos miRNAs oncogênicos do cluster miR-17-92 e restaurando os níveis protéicos de Smad4 por interferir na via de sinalização Notch. / Iodine excess blocks cell proliferation and inhibits hormone synthesis, while delays oncogenic effects of RET/PTC3 activation in thyroid follicular cells. BRAF mutation (T1799A) is the most prevalent genetic alteration in thyroid cancer, and transgenic mice model for BRAF develops thyroid cancer that progress to aggressive histotypes. High levels of microRNAs (miRNAs) of miR-17-92 cluster are associated to aggressive thyroid cancer and modulate translation of target mRNAs in oncogenic signaling pathways. In this study, we evaluated the influence of high dose iodine in miRNAs under BRAF oncogene activation, and its effects in thyroid follicular cell biology. BRAF induction induces high expression of miR-17-92 while high dose iodine blocks this effect in thyroid follicular cells. miR-19 inhibits Smad4 translation and impairs TGFb signaling transduction, effect reverted by iodine. Iodine modulates miR-17-92 expression by interfering in BRAF-induced Notch signaling activation. These results indicate that iodine protects thyroid follicular cell during BRAF induction, reverting oncogenic miR-17-92 activation and restoring protein levels of Smad4 by Notch signaling modulation.

Le côlon des mammifères est colonisé d'environ 1013 bactéries. Si ce microbiote contribue au métabolisme, au développement et à la protection de l'organisme et représente une source massive d'antigènes. Il doit donc être compartimenté afin d'empêcher leur dissémination dans l'organisme où il pourrait être délétère. Lors de ma thèse, je me suis intéressé au rôle du Transforming Growth Factor beta (TGF-bêta, une cytokine fortement exprimée sous forme inactive au niveau de l'intestin des mammifères. Nous avons pu montrer que l'expression de l'intégrine alphav bêta 8par les lymphocytes T régulateurs (Treg) est essentielle à l'activation du TGF-bêta. Par ailleurs, mes travaux démontrent que deux protéines de la voie de signalisation du TGF-bêta, TIF-1gamma et SMAD4, contrôlent l'expression de l'IL-22 dans les cellules lymphocytaires innées de groupe 3 (ILC3) du côlon, responsable du maintien l'intégrité de la barrière intestinale empêchant l'entrée massive de bactéries et une suractivation des lymphocytes Th17 impliqués dans le développement spontané de cancers colorectaux. Ainsi, mes travaux de recherche ont permis de mettre en évidence le rôle clé du TGF-bêta dans le maintien de l'intégrité intestinale essentiel à la prévention du développement de cancers colorectaux induits spontanément par le microbiote / Mammalian colon harbors about 1013 bacteria. Although this microbiota contributes to metabolism, development and protection of the organism, it constitutes a huge source of antigens and must be compartmentalized in order to prevent intestinal bacteria dissemination in the organism that could be harmful for the host. During my PhD, I was interested in the role of Transforming Growth Factor beta (TGF-beta, a highly expressed cytokine and produced as an inactive form in mammalian gut. We showed that the expression of integrin alpha v beta 8by regulatory T cells (Treg) is essential to activate TGF-beta. Moreover, my work revealed that two proteins of the TGF-beta signaling pathway, TIF-1gamma and SMAD4, are responsible for the control of the expression of IL-22 within colonic group 3 Innate Lymphoid Cells (ILC3) which maintains the intestinal barrier integrity and prevents bacteria from entering and over-activation of Th17 cells involved in spontaneous colorectal cancer development. My work revealed a key role for TGF-beta in the maintenance of intestinal barrier-integrity essential to prevent spontaneous microbiota-induced colorectal cancer development

Le TGFbeta intervient dans la régulation de nombreux processus cellulaires comme la prolifération, la différenciation, la migration, l'apoptose, du développement embryonnaire jusqu'à la vie adulte. Le TGFbeta est aujourd'hui bien décrit pour son rôle de suppresseur de tumeur de par ses activités anti-prolifératives et pro-apoptotiques, en particulier sur les cellules épithéliales. Cependant, au cours de la progression tumorale, le TGFbeta devient un promoteur de tumeur en favorisant l'angiogenèse, l'échappement de la tumeur vis-à-vis du système immunitaire et en induisant la transition épithélio-mésenchymateuse. Après fixation du ligand TGFbeta , le complexe de récepteurs active les protéines cytoplasmiques Smad2 et Smad3 qui s'associent à Smad4 pour former le complexe transcriptionnel qui se transloque alors dans le noyau pour réguler la transcription de nombreux gènes cibles. Récemment, la protéine TIF1gamma a été décrite pour intervenir dans la régulation négative de la voie du TGFbeta , en monoubiquitinant Smad4 ou en interagissant avec Smad2/3 en compétition avec Smad4. Cette voie de signalisation devant être finement contrôlée pour cibler son action en fonction du contexte cellulaire, nous analysons ici la régulation des interactions fonctionnelles entre la voie canonique du TGFbeta et la protéine TIF1gamma. Dans cette étude, nous montrons que TIF1gamma agit comme un régulateur négatif des fonctions de Smad4 dans la voie de signalisation du TGFbeta au cours du processus de transition épithélio-mésenchymateuse et au cours de la différenciation terminale des cellules épithéliales mammaires et de la lactation. Nous étudions également la SUMOylation de TIF1gamma comme nouveau niveau de régulation de la réponse cellulaire au TGFbeta . Nous avons ainsi caractérisé les sites fonctionnels de SUMOylation de TIF1gamma et montré que cette modification post-traductionnelle inhibe la formation du complexe transcriptionnel Smad et est nécessaire pour réguler temporellement la résidence de Smad4 au niveau du promoteur de gènes cibles du TGFbeta . Nos résultats montrent le rôle important de la SUMOylation de TIF1gamma dans la régulation de la transition épithélio-mésenchymateuse induite par le TGFbeta . En conclusion, notre travail met en avant le rôle majeur de TIF1gamma dans la régulation de la réponse transcriptionnelle au TGFbeta . De plus, nous montrons que la SUMOylation de TIF1gamma est nécessaire à son activité répressive sur Smad4 / The cytokine TGFbeta regulates several cellular processes such as proliferation, differentiation, migration and apoptosis, from embryonic development to adulthood. TGFbeta is well described for its tumor suppressor role through antiproliferative and proapoptotic activities, in particular in epithelial cells. During tumor progression however, TGFbeta becomes a tumor promotor, favoring angiogenesis, immune suppression and inducing the epitheliomesenchymal transition. Binding of TGFbeta ligand to its receptors activate cytoplasmic messenger Smad2 and Smad3 to complex with Smad4 and shuttle into the nucleus to regulate TGFbetatarget genes expression. Recently, TIF1gamma has been described as a new negative regulator of TGFbeta signaling, through monoubiquitination of Smad4 or direct competition with Smad4 to bind activated Smad2/3. This signaling pathway has to be finely tuned to target an action dependent on a cellular context, which is why we analyze here the regulation of functional interactions between the TGFbeta canonical signaling and TIF1gamma. In this study, we show that TIF1gamma acts as a negative regulator of Smad4 functions in TGFbetasignaling during the epithelio-mesenchymal transition and during terminal differentiation of mammary epithelial cells and lactation. We are also interested in studying TIF1gamma SUMOylation as additional level of regulation of cell response to TGFbeta. Thus we characterized four functional SUMOylation sites in TIF1gamma and we found that this post-translational modification inhibits the formation of Smads transcriptional complex and is needed to temporally restrict Smad4 residence on the promoter of TGFbetatarget genes. Our results show the critical role of TIF1gamma SUMOylation in the regulation of TGFbeta- induced epithelio-mesenchymal transition. As a conclusion, our study unveils the major role of TIF1gamma in the regulation of TGFbeta transcriptional responses. Moreover, we show that TIF1gamma requires SUMOylation to exert its repressive activity on TGFbetasignaling

Colon and breast cancers are amongst the leading causes of cancer deaths in the United States, mostly attributed to metastasis and resistance to therapy. Hence, there is a critical need to identify novel biomarkers for effective prognosis and to design targeted therapies to combat the metastatic diseases. Loss of heterozygosity (LOH) at chromosome 18q and inactivation of the target gene, SMAD4, corresponds to resistance to the common chemotherapeutic agent, 5-fluorouracil (5-FU), in colon cancer. Our examination of the therapeutic resistance phenomenon in SMAD4-negative colon cancer cells with the three common agents revealed significant resistance to both 5-FU and irinotecan but not to oxaliplatin. We also followed up with the earlier findings from our group, which suggested that SMAD4 might interact with metastasis-promoting factors to suppress metastatic progression and render sensitivity to chemotherapy. Co-immunoprecipitation and mass spectrometry analysis revealed that SMAD4 interacts with and inhibits RICTOR, a component of mTORC2 that activates oncogenic AKT via phosphorylation at Serine 473. Overexpression of SMAD4, depletion of RICTOR, or inhibition of AKT signaling restores sensitivity to irinotecan in SMAD4-negative colon cancer cells in vitro. Furthermore, as expected pharmacological inhibition of AKT sensitizes these cells to irinotecan in vivo. Interestingly, high RICTOR/AKT expression correlates with worse survival in colon cancer patients, suggesting them as novel prognostic biomarkers and therapeutic targets. On the other hand, triple-negative breast cancer (TNBC) is the most aggressive form of breast cancer due to lack of effective targeted therapies. Using miRNA expression profiling of a model for epithelial-mesenchymal transition in TNBC, we found suppression of miR-4417 during the progression from non-malignant to malignant stage. Furthermore, localization of miR-4417 to chromosome 1p36, a region corresponding to high frequency of LOH in multiple cancers and low-level expression in TNBC patients associated with poor overall survival is consistent with its likely role as a tumor suppressor. Interestingly, we found that overexpression of miR-4417 is sufficient to inhibit migration and tumorigenecity of TNBC cells in vitro. Overall, our findings suggest miR-4417 exerts a tumor-suppressive effect and could serve as a novel prognostic biomarker and therapeutic tool against TNBC. / 2021-02-20T00:00:00Z

<p>Pancreatic endocrine tumors (PETs) occur sporadically or in the familial multiple endocrine neoplasia type 1 (MEN1) syndrome, whereas midgut carcinoids are nonfamilial, malignant endocrine tumors of the intestine. For these tumor entities morphological criteria are of limited use for prognostic prediction and selection of treatment. Genetic characterization may give additional information of clinical use and reveal pathways involved in tumor development.</p><p>Molecular genetic alterations in sporadic and MEN1-associated PETs and midgut carcinoids were studied with LOH and mutational analysis. In addition, immunohistochemistry was used to clarify gene expression. Detected genetic aberrations were correlated to the disease course of individual patients.</p><p>Somatic mutations of the<i> MEN1</i> gene at chromosome <i>11q13</i> were detected in 1/3 of sporadic PETs<i>. </i>Moreover, LOH was found in 70% of the lesions. All tumors with somatic <i>MEN1</i> mutations displayed loss of the remaining allele showing that the <i>MEN1</i> gene is involved in development of sporadic PETs.</p><p> Sporadic and MEN1 PETs were analyzed for LOH at <i>3p,</i> <i>11q13</i> and <i>18q</i>. A relation of LOH at <i>11q13</i> and <i>3p</i> to malignancy was found for the sporadic tumors. None of the benign tumors (all of them insulinomas) had allelic loss at <i>3p</i> or <i>11q13</i>, versus 92 % (p<0.01) of the malignant tumors (including malignant insulinomas). 1/4 of both sporadic and MEN1 lesions displayed LOH at <i>18q</i>, without altered <i>Smad4/DPC4</i>.</p><p>Genome-wide LOH screening of MEN1 PETs revealed multiple allelic deletions without general correlation to tumor size or malignancy. All tumors displayed LOH at the <i>MEN1 </i>locus, and 30% on chromosomes 3, 6, 8, 10, 18 and 21. Intratumoral heterogeneity was revealed, with chromosome 6 and 11 deletions in most tumor cells. Chromosome 6 deletions were mainly found in lesions from patients with malignant features. </p><p>A similar genome-wide LOH screening was performed on midgut carcinoids. Deletions at chromosome <i>18q</i> were found in 88% of the tumors indicating a potential tumor suppressor locus.</p>

Pancreatic endocrine tumors (PETs) occur sporadically or in the familial multiple endocrine neoplasia type 1 (MEN1) syndrome, whereas midgut carcinoids are nonfamilial, malignant endocrine tumors of the intestine. For these tumor entities morphological criteria are of limited use for prognostic prediction and selection of treatment. Genetic characterization may give additional information of clinical use and reveal pathways involved in tumor development. Molecular genetic alterations in sporadic and MEN1-associated PETs and midgut carcinoids were studied with LOH and mutational analysis. In addition, immunohistochemistry was used to clarify gene expression. Detected genetic aberrations were correlated to the disease course of individual patients. Somatic mutations of the MEN1 gene at chromosome 11q13 were detected in 1/3 of sporadic PETs. Moreover, LOH was found in 70% of the lesions. All tumors with somatic MEN1 mutations displayed loss of the remaining allele showing that the MEN1 gene is involved in development of sporadic PETs. Sporadic and MEN1 PETs were analyzed for LOH at 3p, 11q13 and 18q. A relation of LOH at 11q13 and 3p to malignancy was found for the sporadic tumors. None of the benign tumors (all of them insulinomas) had allelic loss at 3p or 11q13, versus 92 % (p&lt;0.01) of the malignant tumors (including malignant insulinomas). 1/4 of both sporadic and MEN1 lesions displayed LOH at 18q, without altered Smad4/DPC4. Genome-wide LOH screening of MEN1 PETs revealed multiple allelic deletions without general correlation to tumor size or malignancy. All tumors displayed LOH at the MEN1 locus, and 30% on chromosomes 3, 6, 8, 10, 18 and 21. Intratumoral heterogeneity was revealed, with chromosome 6 and 11 deletions in most tumor cells. Chromosome 6 deletions were mainly found in lesions from patients with malignant features. A similar genome-wide LOH screening was performed on midgut carcinoids. Deletions at chromosome 18q were found in 88% of the tumors indicating a potential tumor suppressor locus.

Thesis (Ph.D.)--University of Alabama at Birmingham, 2009. / Title from first page of PDF file (viewed on June 10, 2009). Includes bibliographical references.

Pancreatic ductal adenocarcinoma (PDAC) is a serious oncological disease, which ranks among cancers with the worst prognosis and a three-year life expectancy of 10%. Ex-vivo organoid cultures derived from cancer tissue are popular and reliable research models, which reflect the morphology and histology of the original tissue. Genetic background leading to development PDAC confer typical alterations in genes KRAS, TP53, SMAD4 a CDKN2A. The aim of this thesis was to determine mutations present in organoid cultures derived from human PDAC. We used online genomic databases to estimate specific mutations typical for PDAC. Based on that research we designed protocols for the detection of PDAC genetic alterations and optimized those methods using cultured cells. We applied the approach on primary ex- vivo organoids derived from surgical cancer specimens and detected mutations in KRAS, TP53, SMAD4, or deletion of exons in CDKN2A. Alternatively, we proposed improvements for the analysis of genetic background in PDAC. The data obtained within this thesis will be used for the stratification of metabolomics and biochemical analyses further in the project.